BR9913626A - Formulações de ranolazina de liberação contìnua - Google Patents

Formulações de ranolazina de liberação contìnua

Info

Publication number
BR9913626A
BR9913626A BR9913626-0A BR9913626A BR9913626A BR 9913626 A BR9913626 A BR 9913626A BR 9913626 A BR9913626 A BR 9913626A BR 9913626 A BR9913626 A BR 9913626A
Authority
BR
Brazil
Prior art keywords
ranolazine
continuous release
aqueous media
formulations
ranolazine formulations
Prior art date
Application number
BR9913626-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew A Wolff
Fiona Baker
John Langridge
Original Assignee
Cv Therapeutics Inc
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9913626(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc, Syntex Inc filed Critical Cv Therapeutics Inc
Publication of BR9913626A publication Critical patent/BR9913626A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
BR9913626-0A 1998-09-10 1999-09-09 Formulações de ranolazina de liberação contìnua BR9913626A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020967 WO2000013686A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (1)

Publication Number Publication Date
BR9913626A true BR9913626A (pt) 2001-12-04

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9913553-1A BR9913553A (pt) 1998-09-10 1999-09-09 Formulação de ranolazina de liberação sustentada
BR9913626-0A BR9913626A (pt) 1998-09-10 1999-09-09 Formulações de ranolazina de liberação contìnua

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9913553-1A BR9913553A (pt) 1998-09-10 1999-09-09 Formulação de ranolazina de liberação sustentada

Country Status (33)

Country Link
US (14) US6303607B1 (Direct)
EP (3) EP1527779A1 (Direct)
JP (2) JP3745621B2 (Direct)
KR (1) KR100475759B1 (Direct)
CN (2) CN1193757C (Direct)
AR (3) AR022085A1 (Direct)
AT (2) ATE285774T1 (Direct)
AU (4) AU760435B2 (Direct)
BR (2) BR9913553A (Direct)
CA (2) CA2343376C (Direct)
CY (1) CY2008020I2 (Direct)
CZ (2) CZ301341B6 (Direct)
DE (3) DE122008000065I1 (Direct)
DK (2) DK1109558T3 (Direct)
ES (2) ES2234302T3 (Direct)
FR (1) FR09C0001I2 (Direct)
GE (1) GEP20053420B (Direct)
HK (1) HK1044284B (Direct)
HU (2) HUP0104088A3 (Direct)
IL (6) IL141892A0 (Direct)
LU (1) LU91504I2 (Direct)
MX (2) MXPA01002599A (Direct)
NL (1) NL300371I2 (Direct)
NO (4) NO319434B1 (Direct)
NZ (2) NZ510386A (Direct)
PL (3) PL196263B1 (Direct)
PT (2) PT1096937E (Direct)
RU (2) RU2214233C2 (Direct)
SI (2) SI1096937T1 (Direct)
TR (2) TR200101262T2 (Direct)
TW (1) TWI241911B (Direct)
UA (2) UA75027C2 (Direct)
WO (2) WO2000013686A2 (Direct)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
NZ520780A (en) 2000-02-18 2006-04-28 Cv Therapeutics Inc Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
WO2003084517A2 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules d’amoxicilline
KR101061351B1 (ko) 2002-04-09 2011-08-31 플라멜 테크놀로지스 활성 성분 마이크로캡슐의 경구 현탁액
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
ES2523873T3 (es) 2002-05-21 2014-12-02 Gilead Sciences, Inc. Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
CA2593593A1 (en) * 2005-01-06 2006-07-13 Cv Therapeutics, Inc. Sustained release pharmaceutical formulations comprising ranolazine
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
EP1909767A2 (en) * 2005-07-28 2008-04-16 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
EP1998387B1 (en) * 2006-03-17 2015-04-22 Konica Minolta Holdings, Inc. Organic electroluminescent device, display and illuminating device
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
EP2136780A1 (en) * 2007-02-13 2009-12-30 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
US20080312247A1 (en) * 2007-06-13 2008-12-18 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
AU2009212254A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of Ranolazine for treating pain
EP2429526A1 (en) * 2009-05-14 2012-03-21 Gilead Sciences, Inc. Ranolazine for the treatment of cns disorders
WO2010137040A2 (en) 2009-05-28 2010-12-02 Lupin Limited Novel pharmaceutical compositions of ranolazine
MX2012003362A (es) 2009-09-25 2012-06-27 Lupin Ltd Composicion de liberación sostenida de ranolazina.
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (Direct) 2011-07-01 2018-04-28
AU2012312266A1 (en) 2011-09-21 2013-05-02 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176567A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Pharmaceutical compositions comprising vanoxerine and antianginal compounds, and methods of administration of the same for treating episodes of cardiac arrhythmia, maintaining normal sinus rhythm, preventing recurrence of cardiac arrhythmia, and treatment of chronic cardiac arrhythmia in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
TW201717919A (zh) 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics, Inc. LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
EP4456897A4 (en) 2021-12-31 2025-12-10 Tenax Therapeutics Inc ORAL FORMULATIONS OF LEVOSIMENDAN FOR THE TREATMENT OF PULMONARY HYPERTENSION WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
EP0407780B1 (en) * 1989-06-23 1996-09-11 Syntex (U.S.A.) Inc. Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine

Also Published As

Publication number Publication date
CN1321088A (zh) 2001-11-07
DK1096937T3 (da) 2005-05-09
CN1193757C (zh) 2005-03-23
PL196668B1 (pl) 2008-01-31
HK1040060A1 (en) 2002-05-24
IL141893A0 (en) 2002-03-10
RU2214233C2 (ru) 2003-10-20
CZ2001879A3 (cs) 2001-08-15
US6503911B2 (en) 2003-01-07
PL202207B1 (pl) 2009-06-30
NO2009005I1 (no) 2009-03-16
DE69922964D1 (de) 2005-02-03
LU91504I2 (fr) 2009-02-03
CA2343376C (en) 2007-01-09
DE69922964T2 (de) 2005-12-08
NO20011191D0 (no) 2001-03-08
AR053440A2 (es) 2007-05-09
CZ2001880A3 (cs) 2001-08-15
CZ301375B6 (cs) 2010-02-03
US20060217397A1 (en) 2006-09-28
GEP20053420B (en) 2005-01-25
NZ510384A (en) 2002-10-25
CN1211086C (zh) 2005-07-20
NO20011191L (no) 2001-04-30
NL300371I1 (nl) 2009-02-02
ATE285774T1 (de) 2005-01-15
US6525057B2 (en) 2003-02-25
TWI241911B (en) 2005-10-21
PT1109558E (pt) 2002-10-31
HK1044284B (zh) 2005-07-15
AR022085A1 (es) 2002-09-04
TR200101261T2 (tr) 2002-05-21
US20040029890A1 (en) 2004-02-12
WO2000013687A3 (en) 2000-06-29
US20060147521A1 (en) 2006-07-06
TR200101262T2 (tr) 2001-12-21
MXPA01002599A (es) 2005-02-17
IL141892A0 (en) 2002-03-10
AU2008207707A1 (en) 2008-09-25
LU91504I9 (Direct) 2019-01-02
US6852724B2 (en) 2005-02-08
WO2000013686A3 (en) 2000-07-06
JP2006096757A (ja) 2006-04-13
AU2008207703A1 (en) 2008-09-25
CZ301341B6 (cs) 2010-01-20
WO2000013687A2 (en) 2000-03-16
KR20010089874A (ko) 2001-10-12
US6617328B2 (en) 2003-09-09
AU760435B2 (en) 2003-05-15
DE69901570T2 (de) 2003-01-09
EP1527779A1 (en) 2005-05-04
MXPA01002598A (es) 2002-04-08
EP1109558A2 (en) 2001-06-27
HUP0104088A2 (hu) 2002-05-29
US20030166659A1 (en) 2003-09-04
CY2008020I1 (el) 2010-07-28
US20030099705A1 (en) 2003-05-29
IL141892A (en) 2006-08-20
SI1096937T1 (en) 2005-04-30
NO320986B1 (no) 2006-02-20
UA75027C2 (uk) 2006-03-15
DK1109558T3 (da) 2002-08-26
IL141893A (en) 2008-08-07
IL175371A0 (en) 2006-09-05
PL348249A1 (en) 2002-05-20
US6864258B2 (en) 2005-03-08
HUP0103844A2 (hu) 2002-04-29
NZ510386A (en) 2003-08-29
AR052921A1 (es) 2007-04-11
BR9913553A (pt) 2001-10-23
NO2009005I2 (Direct) 2010-06-28
US6303607B1 (en) 2001-10-16
CY2008020I2 (el) 2010-07-28
NO319434B1 (no) 2005-08-15
CA2342390A1 (en) 2000-03-16
EP1096937B9 (en) 2007-02-28
US20020004506A1 (en) 2002-01-10
US20040097514A1 (en) 2004-05-20
EP1109558B1 (en) 2002-05-22
FR09C0001I1 (Direct) 2009-02-27
JP2002524416A (ja) 2002-08-06
US6562826B1 (en) 2003-05-13
CA2342390C (en) 2006-08-29
US20050153982A1 (en) 2005-07-14
HUP0103844A3 (en) 2002-11-28
ES2177346T3 (es) 2002-12-01
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
AU6036499A (en) 2000-03-27
NO20011192L (no) 2001-04-30
ES2234302T3 (es) 2005-06-16
ATE217794T1 (de) 2002-06-15
UA67793C2 (uk) 2004-07-15
AU744071B2 (en) 2002-02-14
PL196263B1 (pl) 2007-12-31
JP3745621B2 (ja) 2006-02-15
CA2343376A1 (en) 2000-03-16
IL180864A0 (en) 2007-07-04
US20030100566A1 (en) 2003-05-29
DE69901570D1 (de) 2002-06-27
HUP0104088A3 (en) 2002-12-28
HK1044284A1 (en) 2002-10-18
US20050059667A1 (en) 2005-03-17
US20020090396A1 (en) 2002-07-11
DE122008000065I1 (de) 2009-04-09
AU6142599A (en) 2000-03-27
NO20011192D0 (no) 2001-03-08
SI1109558T1 (en) 2002-10-31
EP1096937B1 (en) 2004-12-29
KR100475759B1 (ko) 2005-03-10
US6620814B2 (en) 2003-09-16
CN1354665A (zh) 2002-06-19
PT1096937E (pt) 2005-04-29
HU224215B1 (hu) 2005-06-28
EP1096937A2 (en) 2001-05-09
RU2207856C2 (ru) 2003-07-10
FR09C0001I2 (Direct) 2009-12-18
NL300371I2 (nl) 2009-10-01
NO20054324L (no) 2001-04-30
US6369062B1 (en) 2002-04-09

Similar Documents

Publication Publication Date Title
BR9913626A (pt) Formulações de ranolazina de liberação contìnua
BR0109091A (pt) Formulações de ranolazina de liberação sustentada
PT768867E (pt) Forma de dosagem para a administracao de droga em formulacao liquida
TR200302105T4 (tr) Siklosporin, hiyalüronik asit ve polisorbat içeren göz formülasyonları.
BR0107869A (pt) Composições farmacêuticas eletrogiradas
KR900701325A (ko) 속방성 구강 투여용 정제
BR9917012A (pt) Comprimido matricial, permitindo a liberação prolongada de gliclazida, após administração por via oral
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
DE69940674D1 (de) Orale verabreichung von adenosin analogen
BR9913135A (pt) Formulação oral
KR970025615A (ko) 암 전이 억제제
HUP9801414A2 (hu) Nátrium-alginátot és kálium-bikarbonátot tartalmazó folyékony vizes gyógyszerkészítmények
DK0973546T3 (da) Stabiliserede formuleringer med human papillomavirus
BR9611571B1 (pt) composiÇço farmacÊutica estÁvel, kit para administraÇço de ngf e produto medicinal.
BRPI0014878B8 (pt) composição farmacêutica contendo ciclosonida para aplicação à mucosa
FI891865A0 (fi) Laekemedel som innehaoller azelastin med kontrollerad frigoering av det verksamma aemnet.
BR0010521A (pt) Composições farmacêuticas destinadas a administração por via oral de floroglucinol e sua preparação
ZA934573B (en) Preparation for topical use
DE69408579D1 (de) Asserlösliche pharmazeutische zusammensetzungen, die östronderivate und kalziumsalze enthalten
ZA91115B (en) Topical compositions
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
BR9811177A (pt) Composto, composição farmacêutica, e, uso do composto
EP0791350A3 (de) Mittel zur dauerhaften Verformung von menschlichen Haaren
PT1299114E (pt) Composicao farmaceutica de diclofenac com base em vitamina e, papina e hialuronidase
KR20010071581A (Direct)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SYNTEX (USA), LLC. (US) , ROCHE PALO ALTO LLC (US)

Free format text: TRANSFERIDO DE: CV THERAPEUTICS, INC.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ARTIGO 8O COMBINADO COM ARTIGO 13 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]